Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 9/20 | 0.46 |
| ▸ | EGFR | P00533 | 6/20 | 0.45 |
| ▸ | BTK | Q06187 | 3/20 | 0.45 |
| ▸ | ITK | Q08881 | 3/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | NEK2 | P51955 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4204794 | 0.84 | SYK (0.58) | SYKEGFRBTKITKCDK2 | |
| SCHEMBL4199946 | 0.79 | SYK (0.50) | SYKEGFRBTKITKCCNT1 | |
| SCHEMBL4209984 | 0.75 | SYK (0.49) | SYKEGFRBTKITKCDK2 | |
| SCHEMBL4213170 | 0.74 | SYK (0.49) | SYKEGFRNEK2AURKAJAK1 | |
| SCHEMBL4970415 | 0.73 | AURKA (0.55) | SYKEGFRBTKITKCDK2 | |
| SCHEMBL10187811 | 0.73 | SYK (0.59) | SYKBTKITKCCNT1CCNE1 | |
| SCHEMBL1474794 | 0.73 | SYK (0.67) | SYKEGFRBTKITKCCNT1 | |
| SCHEMBL4972364 | 0.70 | JAK3 (0.55) | SYKEGFRBTKITKCCNT1 | |
| SCHEMBL1473979 | 0.69 | JAK3 (0.52) | SYKEGFRBTKITKCCNT1 | |
| SCHEMBL4973658 | 0.69 | JAK3 (0.56) | SYKEGFRBTKITKCCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729087-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120213795-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | disclosed |
| US-8193197-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20080194603-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120213795-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK2, JAK1, JAK3 | SYK 42/4885EGFR 402/4885BTK 9/4885 |
| US-20080194603-A1 | Prevent transplant rejection; autoimmune diseases | JAK1, JAK3, JAK2 | SYK 162/4885EGFR 1582/4885BTK 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.